Cargando…
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor
Tumor hypoxia, a feature of many solid tumors including ovarian cancer, is associated with resistance to therapies. We previously demonstrated that hypoxic exposure results in increased expression of phosphorylated signal transducer and activator of transcription 3 (pSTAT3). We hypothesized the acti...
Autores principales: | McCann, Georgia A., Naidu, Shan, Rath, Kellie S., Bid, Hemant K., Tierney, Brent J., Suarez, Adrian, Varadharaj, Saradhadevi, Zhang, Jianying, Hideg, Kálmán, Houghton, Peter, Kuppusamy, Periannan, Cohn, David E., Selvendiran, Karuppaiyah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278289/ https://www.ncbi.nlm.nih.gov/pubmed/25594014 |
Ejemplares similares
-
Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs
por: Rath, Kellie S, et al.
Publicado: (2013) -
High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer
por: Wallbillich, John J., et al.
Publicado: (2017) -
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols
por: Bratasz, Anna, et al.
Publicado: (2008) -
Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12
por: Bid, Hemant K., et al.
Publicado: (2012) -
A Novel Curcumin Analog (H-4073) Enhances the Therapeutic Efficacy of Cisplatin Treatment in Head and Neck Cancer
por: Kumar, Bhavna, et al.
Publicado: (2014)